Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 416

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 416
---
 |   |             0 | %   |     |   |             0 | %   |
| Risk free rate                             |     |   |            4.35 | %   |     |   |          4.04 | %   |     |   |          4.06 | %   |

| * | The share price used in the determination of the fair value of the ADS warrants granted in 2023 was the ADS price on the date of grant. |

| F-76 |

| 25 | Capital commitments |

The Group had no capital
commitments at 31 December 2023, 31 December 2022 and 31 December 2021.

| 26 | Related party transactions |

There were no related party transactions in the current
or prior periods other than Directors’ remuneration.

| 27 | Contingent liabilities |

The Company entered
into an Arrangement Agreement with Bioasis on 13 December 2022 as amended on 18 December 2022. Under the agreement the Company agreed
to acquire the entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$7.4 million (c£4.4 million).
The agreement was subject to shareholder approval. On 23 January 2023 at the General Meeting to approve the Arrangement Agreement none
of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not proceed. Under the agreement the Company agreed
to reimburse Bioasis US$225,000 expenses relating to the transaction should the Company’s shareholders not approve the transaction.
On 3 March 2023 the Company advised Bioasis that it would offset this liability against the sums it advanced as disclosed in note 13.

As at 31 December 2023
and 31 December 2022 the Company had a contingent liability of $225,000 in relation to this potential liability.

| 28 | Ultimate controlling party |

The Directors do not
consider that there is an ultimate controlling party.

| 29 | Post Balance Sheet Events |

On 22 January 2024
membership of the Board Committees were changed to the following:

| Schedule of share consolidation |                 |                        |                       |
|                                 | Audit Committee | Remuneration Committee | Nominations Committee |
| Stephen Parker                  | X               |                        | X*                    |
| Sijmen de Vries                 |                 | X*                     | X                     |
| Ann Merchant                    | X               | X                      |                       |